IP Library Granted Patent US 7,514,074
Granted Patent B2
US 7,514,074 · App. 10/690,435 · Granted Apr 7, 2009

Cardiac muscle regeneration using mesenchymal stem cells

Assignee: Osiris Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,514,074
App. No.
10/690,435
Granted
Apr 7, 2009
Kind
B2
Abstract

Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

Claims (8)

1. A method of improving ventricular wall motion of the heart of an individual, comprising:

administering to said individual autologous or allogeneic mesenchymal stem cells, wherein said mesenchymal stem cells are administered in an amount effective to improve ventricular wall motion of the heart of said individual.

2. The method of claim 1 wherein said mesenchymal stem cells are administered directly to at least one damaged portion of heart tissue.

3. The method of claim 2 wherein the mesenchymal stem cells are administered by injection.

4. The method of claim 3 wherein the mesenchymal stem cells are administered in a pharmaceutically acceptable liquid injectable carrier.

5. The method of claim 2 wherein the mesenchymal stem cells are administered during an open surgical procedure.

6. The method of claim 5 wherein said mesenchymal stem cells are administered by injection.

7. The method of claim 1 wherein the mesenchymal cells are administered intravenously.

Assignments (4)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0917 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 072297/0753 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST INTERNATIONAL SARL
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2013
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 031533/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2004
From: PITTENGER, MARK F.; GORDON, STEPHEN L.; MACKAY, ALASTAIR MORGAR; MARTIN, BRADLEY J.
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 014959/0831 →
Continuity (5)
Continuation In Part 1027814800 · Oct 22, 2002
Continuation In Part 1012773700 · Apr 22, 2002
Continuation 0944695200
Provisional Application 6005291000 · Jul 14, 1997
Related Publication 20050112104A1 · May 26, 2005